---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-007293"
form_type: "8-K"
ticker: "APTOF"
cik: "0000882361"
company_name: "Aptose Biosciences Inc."
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:45:05.071857+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aptose reports Q3 net loss $5.1M, cash $1.6M, but TUS+VEN+AZA shows 100% CR/CRh at higher doses

## Summary
- Net loss $5.1M (-$2.01/share) for Q3 2025 vs $7.0M (-$11.33/share) in Q3 2024; nine-month net loss $17.7M.
- Cash and equivalents $1.6M as of Sep 30, 2025; company states insufficient cash to fund operations, relying on Hanmi advances.
- TUS+VEN+AZA triplet: 6/6 (100%) achieved CR/CRh at 80/120 mg TUS doses, exceeding 66% expected from VEN+AZA alone; overall 9/10 (90%) CR/CRh.
- Dose escalation to 160 mg TUS underway; updated data to be presented at ASH December 2025.
- Shareholders' deficit of $19.5M; company actively pursuing financing and cost reductions.

## SEC filing metadata
- accession: 0001171843-25-007293
- form_type: 8-K
- ticker: APTOF
- cik: 0000882361
- company_name: Aptose Biosciences Inc.
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882361/000117184325007293/0001171843-25-007293-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882361/000117184325007293/f8k_111325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-007293
- JSON: https://secwatch.observer/filing/0001171843-25-007293.json
- Plain text: https://secwatch.observer/filing/0001171843-25-007293.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.